A multi-marker approach utilizing novel and established cardiac biomarkers provides valuable diagnostic and prognostic information for risk stratification and management of heart failure.
High-sensitivity cardiac biomarkers and multi-biomarker approaches offer improved diagnostic and prognostic capabilities for managing acute and chronic heart failure.
The last decade has seen exciting advances in the field of biomarkers used in managing patients with heart failure (HF). Biomarker research has broadened our knowledge base, shedding more light on the underlying pathophysiological mechanisms occurring in patients with both acute and chronic HF. The criterion required by an ideal cardiovascular biomarker has been progressively changing to an era of sensitive assays that can be used to guide treatment. Recent technological advances have made it possible to rapidly measure even minute amounts of these proteins by means of higher sensitivity assays. With a high prevalence of comorbidities associated with HF, an integrated approach utilizing multiple biomarkers have shown promise in predicting mortality, better risk stratification and reducing re-hospitalizations, thus lowering health-care costs. This review provides a brief insight into recent advances in the field of biomarkers currently used in the diagnosis and prognosis of patients with acute and chronic HF.
Iqbal et al. (2012) conducted a review in Heart failure. Cardiac biomarkers was evaluated. A multi-marker approach utilizing novel and established cardiac biomarkers provides valuable diagnostic and prognostic information for risk stratification and management of heart failure.